Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akio Matsubara

Showing results (111-120 of 191) with videos related to

Pageof 20
Sort By:
Cancer Medicine|August 24, 2017
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinomaHiroyuki Kitano, Yasuhiko Kitadai, Jun Teishima, et al.
Oncology Letters|July 12, 2017
A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patientsKoichi Shoji, Jun Teishima, Tetsutaro Hayashi, et al.
Urologic Oncology|May 21, 2020
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
World Journal of Urology|May 5, 2020
Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infectionHiroyuki Kitano, Norifumi Shigemoto, Yumiko Koba, et al.
The Prostate|October 17, 2018
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patientsYohei Sekino, Naohide Oue, Shoichiro Mukai, et al.
Cancer Science|August 30, 2008
Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancerShinya Ohara, Naohide Oue, Akio Matsubara, et al.
Cancer Letters|November 4, 2019
Prolyl isomerase Pin1 in metabolic reprogramming of cancer cellsYusuke Nakatsu, Takeshi Yamamotoya, Koji Ueda, et al.
Urologic Oncology|March 7, 2020
Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinomaXiangrui Han, Yohei Sekino, Takashi Babasaki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 16, 2017
Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasisJun Teishima, Shinya Ohara, Kousuke Sadahide, et al.
Histopathology|October 22, 2011
Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinomaTetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, et al.
Pageof 20

Showing results (111-120 of 191) with videos related to

Sort By:
Pageof 20
Cancer Medicine|August 24, 2017
Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinomaHiroyuki Kitano, Yasuhiko Kitadai, Jun Teishima, et al.
Oncology Letters|July 12, 2017
A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patientsKoichi Shoji, Jun Teishima, Tetsutaro Hayashi, et al.
Urologic Oncology|May 21, 2020
Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancerYohei Sekino, Xiangrui Han, Takashi Babasaki, et al.
World Journal of Urology|May 5, 2020
Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infectionHiroyuki Kitano, Norifumi Shigemoto, Yumiko Koba, et al.
The Prostate|October 17, 2018
Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patientsYohei Sekino, Naohide Oue, Shoichiro Mukai, et al.
Cancer Science|August 30, 2008
Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancerShinya Ohara, Naohide Oue, Akio Matsubara, et al.
Cancer Letters|November 4, 2019
Prolyl isomerase Pin1 in metabolic reprogramming of cancer cellsYusuke Nakatsu, Takeshi Yamamotoya, Koji Ueda, et al.
Urologic Oncology|March 7, 2020
Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinomaXiangrui Han, Yohei Sekino, Takashi Babasaki, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 16, 2017
Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasisJun Teishima, Shinya Ohara, Kousuke Sadahide, et al.
Histopathology|October 22, 2011
Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinomaTetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, et al.
Pageof 20